Raynaud's phenomenon as a presenting manifestation of ovarian cancer: A case report.
Raynaud's phenomenon
Raynaud's phenomenonchemotherapy
gynecologic oncology
ovarian cancer
paraneoplastic
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
07
05
2020
revised:
19
09
2020
accepted:
07
12
2020
pubmed:
17
12
2020
medline:
22
6
2021
entrez:
16
12
2020
Statut:
ppublish
Résumé
Raynaud's phenomenon (RP) is characterized by episodes of vasospasm affecting the hands and feet. Paraneoplastic RP, as a single presenting symptom is rarely seen in cases of ovarian cancer (OC), and thus may lead to misdiagnosis. We present a case of paraneoplastic RP in a patient with high-grade serous OC. A 66-year-old female presented with dyspnea and bilateral peripheral cyanosis involving her fingers. CA125 was elevated (423 U/mL). CT revealed a pleural effusion on the left side, suspicious omental lesions and ascites. Omental biopsy and pleural cytology demonstrated high-grade serous OC. Neoadjuvant chemotherapy (carboplatin/paclitaxel) resulted in objective improvement in finger ischemia and complete regression of vasospastic features. However, the patient's disease was refractory to post-surgical treatment and eventually she deceased of multiple organ failure. To conclude, RP may be a presenting symptom of OC. It is important to determine the underlying disease and develop an effective treatment strategy.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
855-859Informations de copyright
© 2020 Japan Society of Obstetrics and Gynecology.
Références
Garner R, Kumari R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud's phenomenon: Systematic review and meta-analysis of observational studies. BMJ Open 2015; 5: e006389.
Belch J, Carlizza A, Carpentier PH et al. ESVM guidelines - The diagnosis and management of Raynaud's phenomenon. Vasa 2017; 46: 413-423.
Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL. Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford) 2017; 56: v45-v48.
Musa R, Qurie A. Raynaud Disease (Raynaud Phenomenon, Raynaud Syndrome). Treasure Island, FL: StatPearls, 2020.
Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH. Raynaud's phenomenon: A brief review of the underlying mechanisms. Front Pharmacol 2016; 7: 438.
Schildmann EK, Davies AN. Paraneoplastic Raynaud's phenomenon - Good palliation after a multidisciplinary approach. J Pain Symptom Manage 2010; 39: 779-783.
Hsu STLY, Lie MF. Symmetrical peripheral gangrene of sudden onset a paraneoplastic syndrome? A case report and review of the literature. Dematol Sinica 1996; 14: 82-88.
Oc B. Symmetrical gangrene. BMJ 1884; 1: 640.
Poszepczynska-Guigne E, Viguier M, Chosidow O, Orcel B, Emmerich J et al. Paraneoplastic acral vascular syndrome: Epidemiologic features, clinical manifestations, and disease sequelae. J Am Acad Dermatol 2002; 47: 47-52.
Kohli M, Bennett RM. Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma. J Rheumatol 1995; 22: 1393-1394.
Chow SF, McKenna CH. Ovarian cancer and gangrene of the digits: Case report and review of the literature. Mayo Clin Proc 1996; 71: 253-258.
DeCross AJ, Sahasrabudhe DM. Paraneoplastic Raynaud's phenomenon. Am J Med 1992; 92: 571-572.
Levien TL. Advances in the treatment of Raynaud's phenomenon. Vasc Health Risk Manag 2010; 6: 167-177.
Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45: 677-686.
John D Pauling TS, Domsic RT, Frech TM. Treatment efficacy in secondary Raynaud's phenomenon. Lancet Rheumatol 2020; 2: E132.
Ventura I, Reid P, Jan R. Approach to patients with suspected rheumatic disease. Prim Care 2018; 45: 169-180.
Le Besnerais M, Miranda S, Cailleux N, Girszyn N, Marie I et al. Digital ischemia associated with cancer: Results from a cohort study. Medicine (Baltimore) 2014; 93: e47.
Herrick AL. Evidence-based management of Raynaud's phenomenon. Ther Adv Musculoskelet Dis 2017; 9: 317-329.
Allen D, Robinson D, Mittoo S. Paraneoplastic Raynaud's phenomenon in a breast cancer survivor. Rheumatol Int 2010; 30: 789-792.